- Silence Therapeutics has started dosing the first patient in a Phase IIa part of the current Atu027-I-02 study.

In this study, first-line patients with loco-regionally advanced or metastatic pancreatic cancer are given two different Atu027 treatments on top of the standard gemcitabine regime, the standard chemotherapy for these patients.

In pancreatic cancer, the tumour micro-environment is implicated in fostering tumour growth, invasion and metastasis.

The novel investigational drug combination aims to attenuate further disease progression by combining the anti-neoplastic activity of gemcitabine with the anti-metastatic action of Atu027.

At 8:23am: [LON:SLN] share price was +2.01p at 219.88p

Story provided by